Davies, Andrew <br/><br/>
Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .  [electronic resource] 

 -  Current medical research and opinion  Nov 2008 
 - 3275-85 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-4877 
<br/><br/><label>Standard No.: </label>10.1185/03007990802507547  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Algorithms<br/>Antipsychotic Agents--adverse effects<br/>Aripiprazole<br/>Benzodiazepines--adverse effects<br/>Clinical Trials, Phase I as Topic--economics<br/>Cost-Benefit Analysis<br/>Decision Support Techniques<br/>Follow-Up Studies<br/>Health Care Costs<br/>Health Resources--economics<br/>Humans<br/>Olanzapine<br/>Patient Acceptance of Health Care<br/>Piperazines--adverse effects<br/>Quality-Adjusted Life Years<br/>Quinolones--adverse effects<br/>Randomized Controlled Trials as Topic--economics<br/>Schizophrenia--drug therapy<br/>United Kingdom--epidemiology